Synthesis and Study of Medicinally Important Molecules
Synthesis and Study of Medicinally Important Molecules
批准号:
10620871
负责人:
Mingji Dai
金额:
$42.21万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-08-04 至 2028-07-31
关键词:
AlkaloidsBiologicalBiologyCollectionCommunicable DiseasesComplexDevelopmentDrug IndustryDrug resistanceElementsEvaluationGoalsHealthHumanInstitutionLeadMedicineMethodologyNatural ProductsNatural SelectionsNerve DegenerationOrganic SynthesisOutcomes ResearchProblem SolvingReactionResearchTerpenesTherapeuticanti-cancerantimicrobialbioactive natural productscancer therapychemical synthesiscostdrug discoveryflexibilityin vivoinnovationlead optimizationnervous system disordernovelnovel lead compoundnovel therapeuticsprogramsrational designresearch clinical testingsmall moleculesmall molecule librariestherapeutic development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
The goal of our research program is to innovate the strategy and methodology of organic synthesis and use
these innovations to solve problems of biological and medicinal importance and ultimately impact human
health. Our program focuses on the synthesis and study of both natural and unnatural molecules with potential
for the treatment of cancer, neurological disorders, and drug resistant infectious diseases. We view the
completion of a chemical synthesis as the beginning of a larger and deeper scholarly inquiry. It would enable
us to profile the biology of the selected natural products and rationally designed small molecules, decipher their
mechanism of actions, and optimize the lead compounds into biological probes and novel therapeutics. The
selected terpenoid and alkaloid natural products represent both the state-of-the-art challenges for complex
molecule synthesis as well as promising lead compounds for novel therapeutic development. Their structural
complexity, natural scarcity, and unknown mechanism of actions have significantly hampered their biomedical
development. We aim to fill this gap and move these molecules forward in the drug discovery pipeline with a
multi-faceted approach centered on innovative chemical synthesis. The expected outcomes of this research
will provide (i) new reactions and strategies in the toolbox of both medicinal chemists and synthetic chemists to
prepare functional molecules, (ii) a reliable access to the selected target molecules with therapeutic
importance, (iii) a collection of medicinally relevant molecules featuring structural novelty, complexity, and
diversity for further and larger biological evaluations in academic institutions and pharmaceutical industries,
and (iv) novel anticancer, anti-neurodegenerative and antimicrobial lead compounds with potentially novel
mode of actions for in vivo and clinical evaluations.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.bmc.2020.115678
发表时间:
2020-10-01
期刊:
Bioorganic & medicinal chemistry
影响因子:
3.5
作者:
[Kyei-Baffour K, Davis DC, Boskovic Z, Kato N, Dai M]
通讯作者:
Dai M
DOI:
10.1021/jacs.3c06031
发表时间:
2023-08-30
期刊:
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
影响因子:
15
作者:
[Jiang, Baiyang, Dai, Mingji]
通讯作者:
Dai, Mingji
Purdue Drug Discovery Training Program
-
批准号:10186773
-
项目类别:
-
资助金额:$19.51万
-
财政年份:2019
-
负责人:Mingji Dai
-
依托单位:
Synthesis and Study of Medicinally Important Molecules
-
批准号:10216307
-
项目类别:
-
资助金额:$38.18万
-
财政年份:2018
-
负责人:Mingji Dai
-
依托单位:
Synthesis and Study of Medicinally Important Molecules
-
批准号:10459633
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2018
-
负责人:Mingji Dai
-
依托单位:
Synthesis and Study of Medicinally Important Molecule
-
批准号:10685687
-
项目类别:
-
资助金额:$38.18万
-
财政年份:2018
-
负责人:Mingji Dai
-
依托单位:
Synthesis and Study of Medicinally Important Molecules
-
批准号:9755457
-
项目类别:
-
资助金额:$38.18万
-
财政年份:2018
-
负责人:Mingji Dai
-
依托单位:
Targets, Structures and Drugs (TSD)
-
批准号:10658897
-
项目类别:
-
资助金额:$4.23万
-
财政年份:1998
-
负责人:Mingji Dai
-
依托单位:
Targets, Structures and Drugs (TSD)
-
批准号:10434761
-
项目类别:
-
资助金额:$4.23万
-
财政年份:1998
-
负责人:Mingji Dai
-
依托单位:
Targets, Structures and Drugs (TSD)
-
批准号:10223207
-
项目类别:
-
资助金额:$4.23万
-
财政年份:1998
-
负责人:Mingji Dai
-
依托单位:
海外基金